Goldman Sachs Group Inc. Has $4.53 Million Stock Position in Artivion, Inc. $AORT

Key Points

• Goldman Sachs Group Inc. reduced its stake in Artivion, Inc. by 14.3%, now holding 184,429 shares valued at approximately $4.53 million.
• Several institutional investors increased their positions, with Wellington Management raising theirs by 4.1% and Next Century Growth Investors lifting theirs by an impressive 107.6% in the first quarter.
• Artivion reported an earnings per share (EPS) of $0.24, surpassing analysts' consensus estimates, and achieved a revenue of $112.97 million for the quarter, representing a 15.3% increase from the previous year.

Goldman Sachs Group Inc. lowered its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 14.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 184,429 shares of the company's stock after selling 30,874 shares during the period. Goldman Sachs Group Inc. owned approximately 0.43% of Artivion worth $4,533,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Legacy Advisors LLC bought a new stake in Artivion in the 1st quarter valued at about $28,000. MCF Advisors LLC boosted its holdings in Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares during the period. EntryPoint Capital LLC bought a new stake in Artivion in the 1st quarter valued at about $284,000. ProShare Advisors LLC boosted its holdings in Artivion by 44.7% in the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company's stock valued at $341,000 after purchasing an additional 3,683 shares during the period. Finally, Natixis Advisors LLC boosted its holdings in Artivion by 16.4% in the 1st quarter. Natixis Advisors LLC now owns 12,615 shares of the company's stock valued at $310,000 after purchasing an additional 1,777 shares during the period. Institutional investors own 86.37% of the company's stock.

Artivion Price Performance

AORT stock traded down $0.77 during trading on Friday, reaching $40.59. 1,311,858 shares of the company were exchanged, compared to its average volume of 437,901. The company has a 50-day moving average of $38.34 and a two-hundred day moving average of $30.86. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -96.64 and a beta of 1.69. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $45.07. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.13. The business had revenue of $112.97 million during the quarter, compared to analysts' expectations of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. Artivion's quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity at Artivion

In related news, insider John E. Davis sold 10,802 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the transaction, the insider directly owned 208,778 shares in the company, valued at $9,117,335.26. This represents a 4.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James P. Mackin sold 12,500 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $42.32, for a total transaction of $529,000.00. Following the transaction, the chief executive officer owned 852,783 shares of the company's stock, valued at approximately $36,089,776.56. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 74,858 shares of company stock valued at $3,250,129 in the last quarter. 8.10% of the stock is owned by company insiders.

Analyst Ratings Changes

AORT has been the subject of a number of recent research reports. Stifel Nicolaus boosted their price objective on shares of Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a report on Friday, August 8th. Canaccord Genuity Group upped their price target on shares of Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a report on Friday, August 8th. LADENBURG THALM/SH SH downgraded shares of Artivion from a "buy" rating to a "neutral" rating and upped their price target for the stock from $32.00 to $38.80 in a report on Wednesday, August 13th. JMP Securities upped their price target on shares of Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a report on Friday, August 8th. Finally, Needham & Company LLC upped their price target on shares of Artivion from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $40.63.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.